Hansa Biopharma
Scheelevägen 22
SE-223 63 Lund, Sweden
Phone: +46 46 16 56 70

www.hansabiopharma.com

PRESS RELEASE

Hansa Biopharma to participate in Jefferies Global Healthcare Conference in London

Lund, Sweden, November 10, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat with Farzin Haque, Biotechnology Equity Research Analyst, Jefferies, at the Jefferies Global Healthcare Conference in London, on Tuesday 17 November, at 14:00-14:25 GMT / 09:00-09:25 EST. Hansa Biopharma COO and President US Maria Törnsén, CFO Adam Cutler, CMO Richard Philipson, and VP Business Development Fredrik Röök will also be attending the event.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Fireside chat at Jefferies Global Healthcare Conference in London

Date and Time: Tuesday 17 November, 14:00-14:25 GMT / 09:00-09:25 EST

Moderator: Farzin Haque, Biotechnology Equity Research Analyst, Jefferies

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Webcast: Hansa Biopharma Fireside Chat

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.